Summit Financial’s BioMarin Pharmaceuticals BMRN Stock Holding History

Summit Financial’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-57,628	Closed	-$5.03M	–	490
2024 Q1	$5.03M	Sell	57,628 -931	-2%	-$83.3K	0.3%	45
2023 Q4	$5.65M	Sell	58,559 -5,169	-8%	-$457K	0.37%	36
2023 Q3	$5.64M	Buy	63,728 +1,369	+2%	+$122K	0.42%	32
2023 Q2	$5.41M	Buy	+62,359	New	+$5.87M	0.39%	31

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Summit Financial's BMRN Position: Q2 2024 in Review

Summit Financial sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2024, closing a stake of 57,628 shares — an estimated $5.03M sold.

Summit Financial first reported a position in BMRN in Q2 2023 and held it in 4 quarters. The position peaked at $5.65M in Q4 2023. 559 funds tracked by Wall St. Rank hold BMRN as of Q2 2024.

Summit Financial reported no remaining BioMarin Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Summit Financial sold 57,628 BioMarin Pharmaceuticals shares in Q2 2024, an estimated $5.03M.
Summit Financial first reported a position in BioMarin Pharmaceuticals in Q2 2023 and held it in 4 quarters.
Summit Financial's BioMarin Pharmaceuticals position peaked at $5.65M in Q4 2023.
559 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2024.

Based on Summit Financial's 13F filing for Q2 2024, filed 31 Jul 2024.